503 Background: Early recurrence is common after surgery for hepatocellular carcinoma (HCC) and associated with poor prognosis. There is no standard of care neoadjuvant therapy. The combinations of lenvatinib, anti-PD-1 antibodies and transcatheter arterial chemoembolization (TACE) (triple therapy) has shown better trend in tumor response and survival outcomes on unresectable HCC. This study aims to explore the efficacy and safety of triple therapy in the neoadjuvant therapy of resectable HCC patients with high-risk of recurrence. Methods: This prospective, single-arm, phase 2 trial (ChiCTR2100048249) enrolled patients with primary resectable HCC who had not received prior anti-tumor therapy. TACE will be performed once on Day 1. Tislelizumab (an anti-PD-1 antibody, 200 mg) intravenously once every 3 weeks and lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily was initiated within 7-10 days after TACE treatment. Surgery was performed 8 weeks after treatment. After 4-8 weeks of surgery, patients continued to receive tislelizumab and lenvatinib for 6 months. Primary endpoint was relapse-free survival (RFS). Secondary endpoints were objective response rate (ORR) by mRECIST, major pathological reactions, R0 resection rates, overall survival, and adverse events (AE). Results: From April 2022 to June 2023, 29 patients (median age, 54 years) from ten Chinese hospitals were enrolled, all Child-Pugh A and ECOG PS 0, mostly males (79.3%) and HBV infection (93.1%). According to mRECIST, the ORR was 89.7% (26/29, CR 4, PR 22), and the DCR was 96.7% (28/29). No grade 3 or above AE were observed. The most common AE were rash (4/29, 13.8%), thrombocytopenia (3/29, 10.3%), fatigue (3/29, 10.3%), elevated aspartate aminotransferase (2/29, 6.9%), elevated alanine aminotransferase (2/29, 6.9%), and hypertension (2/29, 6.9%). In 29 patients, 26 patients had received surgical treatment (R0 resection rates were 100%), 20 patients (20/26, 76.9%) achieved major pathological reaction (necrosis > 90%), and 4 patients (4/26, 15.4%) achieved complete pathological response. 2 patient (6.9%) refused surgery. 1 patient (3.4%) developed disease progression and lost the chance of surgery. After a median follow-up of 8.0 months (interquartile range 4.6-12.3 months), one patient died of severe pneumonia caused by COVID-19 infection 9.9 months after operation. Tumor recurrence was detected in 3 patients. The 6- and 12-month RFS rates were 90% and 82.5%, respectively. Median RFS and overall survival were not reached. Conclusions: Lenvatinib, tislelizumab, and TACE were safe and showed promising efficacy as a neoadjuvant therapy for resectable HCC with high risk of recurrence. Clinical trial information: ChiCTR2100048249.
Read full abstract